Inhibition of formate production blocks CD8 + T-cell responses and delays disease onset in a mouse model of type 1 diabetes

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

The one-carbon metabolic pathway is essential for proliferating cells and has recently been identified as an immunomodulatory target in CD4⁺ T cells. However, its role in other immune cell types has not been fully established. We investigated the function of the one-carbon pathway in CD8⁺ T cells, which are the primary effectors responsible for the destruction of pancreatic beta cells that causes type 1 diabetes. Enzymes involved in the one-carbon pathway, as well as levels of formate—a critical intermediate—were upregulated during CD8⁺ T-cell activation. Pharmacological inhibition of MTHFD2, a mitochondrial enzyme involved in one-carbon metabolism, suppressed CD8⁺ T-cell activation, proliferation, and effector function. Mechanistically, this effect was mediated by reduced signaling through KRAS and the mTORC1 downstream targets HIF1α, S6, and STAT3. As previously shown in CD4⁺ T cells, formate supplementation reversed the effects of MTHFD2 inhibition on activation, proliferation, and function of CD8 + T cells, and prevented the reduction of the TCF1 high CD8⁺ progenitor cell population, which has been shown to drive anti-beta cell autoimmunity. Formate levels were elevated in the immune cells isolated from pancreatic lymph nodes during the insulitis stage in non-obese diabetic mice. Treatment of euglycemic non-obese diabetic mice with an MTHFD2 inhibitor during the insulitis stage delayed CD8⁺ T-cell infiltration into pancreatic islets and postponed the onset of type 1 diabetes. These findings reveal a new paradigm for preventing and delaying the onset of type 1 diabetes.

Article activity feed